Protease inhibitors for second-line antiretroviral therapy

Darunavir versus Atazanavir (iStock-1041087778) - for website (2nd row)

Protease inhibitors are a potent class of antiretroviral drugs – but which one reigns supreme as a recommended first choice for second-line antiretroviral therapy?

To access this module, please register or login: